Labtoll

The research confirms accessible computational biology frameworks, enterprise-only drug-discovery providers, and an adjacent wet-lab matching service. It did not find a commercial broker that aggregates the named computational methods into a per-run catalog. That gap is not proof that procurement, licensing, scientific comparability, or demand will work.

Labtoll should not route a compound through an opaque price-times-accuracy score. Methods answer different questions and depend on dataset rights, assay context, endpoint, model version, parameters, hardware, random seed, uncertainty, and qualified interpretation. A predicted structure, binding score, or ADMET estimate is not experimental validation, safety, efficacy, regulatory acceptance, or a clinical claim.

The product coordinates sponsor authorization, provider qualification, confidential submission, reproducible execution evidence, scientific review, deliverables, disputes, and correction. Any regulated computer-software-assurance mapping must be validated for the customer's intended use; an audit packet is not compliance.

Seed and growth biotechnology sponsors that need bounded computational studies but cannot justify a broad enterprise partnership or assemble every provider workflow themselves.